Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 27, 2017
July 06 2017 - 8:00AM
Business Wire
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it
will report its second quarter financial results on Thursday, July
27, 2017 after the close of financial markets. Following the
results announcement, company management will host a conference
call and webcast discussion of the results and provide a general
corporate update. Access to the event can be obtained as
follows:
LIVE access on Thursday, July 27, 20171:30 p.m. Pacific Time /
4:30 p.m. Eastern Time
- Telephone 877-874-1568 (domestic) or
719-325-2484 (international); conference ID 4818690
- Webcast available at
www.seattlegenetics.com in the Investors section
REPLAY access
- Telephone replay will be available
beginning at approximately 4:30 p.m. PT on Thursday, July 27, 2017
through 5:00 p.m. PT on Monday, July 31, 2017 by calling
888-203-1112 (domestic) or 719-457-0820 (international); conference
ID 4818690
- Webcast replay will be available on the
Seattle Genetics website at www.seattlegenetics.com in the
Investors section
About Seattle Genetics
Seattle Genetics is an innovative biotechnology company that
develops and commercializes novel antibody-based therapies for the
treatment of cancer. The company’s industry-leading antibody-drug
conjugate (ADC) technology harnesses the targeting ability of
antibodies to deliver cell-killing agents directly to cancer cells.
ADCETRIS® (brentuximab vedotin), the company’s lead product, in
collaboration with Takeda Pharmaceutical Company Limited, is the
first in a new class of ADCs commercially available globally in 67
countries for relapsed classical Hodgkin lymphoma and relapsed
systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics
is also advancing enfortumab vedotin, an ADC for metastatic
urothelial cancer, in a planned pivotal trial in collaboration with
Astellas. Headquartered in Bothell, Washington, Seattle Genetics
has a robust pipeline of innovative therapies for blood-related
cancers and solid tumors designed to address significant unmet
medical needs and improve treatment outcomes for patients. The
company has collaborations for its proprietary ADC technology with
a number of companies including AbbVie, Astellas, Bayer, Celldex,
Genentech, GlaxoSmithKline and Pfizer. More information can be
found at www.seattlegenetics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170706005400/en/
Seattle Genetics, Inc.InvestorsPeggy Pinkston,
425-527-4160ppinkston@seagen.comorMediaBrandi Robinson,
425-527-2910brobinson@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024